Brief: Caladrius Biosciences And CEND Therapeutics Announce Definitive Merger Agreement

Lisata Therapeutics

27/04/2022 12:10

April 27 (Reuters) - Caladrius Biosciences Inc  CLBS.O :
    * CALADRIUS BIOSCIENCES AND CEND THERAPEUTICS ANNOUNCE DEFINITIVE MERGER
AGREEMENT
    * CALADRIUS BIOSCIENCES AND CEND THERAPEUTICS ANNOUNCE DEFINITIVE MERGER
AGREEMENT
    * CALADRIUS BIOSCIENCES INC - CALADRIUS TO MAKE AN IMMEDIATE INVESTMENT OF
$10
MILLION IN CEND
    * CALADRIUS BIOSCIENCES INC - CEND WILL MERGE WITH A WHOLLY OWNED SUBSIDIARY
OF
CALADRIUS IN AN ALL-STOCK APPROXIMATE "MERGER OF EQUALS"
    * CALADRIUS BIOSCIENCES INC - COMBINED COMPANY WILL BE RENAMED LISATA
THERAPEUTICS, INC
    * CALADRIUS BIOSCIENCES INC - DAVID J. MAZZO, PH.D., CURRENT PRESIDENT AND
CEO OF
CALADRIUS WILL BE CHIEF EXECUTIVE OFFICER OF LISATA
    * CALADRIUS BIOSCIENCES INC - SHAREHOLDERS OF CEND WILL RECEIVE
APPROXIMATELY 60.5
MILLION SHARES OF CALADRIUS COMMON STOCK
    * CALADRIUS BIOSCIENCES INC - TRANSACTION VALUES EACH COMPANY AT $90 MILLION

Source text for Eikon:  ID:nGNXbkGQvk 
Further company coverage:  CLBS.O 

 ((Reuters.Briefs@thomsonreuters.com;))